Adjuvant Chemotherapy for Breast Cancer in Older Adult Patients

References

• Cancer Research UK. Breast cancer statistics (2021). Available from: https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/breast-cancer. Accessed June 20, 2024.
   Google Scholar
• Kubista E. Das Mammakarzinom: Zahlen und Fakten [Breast cancer: figures and facts]. Wien Med Wochenschr. 2001;151(21–23):548–551. German.
   PubMedGoogle Scholar
• Communiqué of the Seventh National Population Census. National Bureau of Statistics of China 2020; 2020.
   Google Scholar
• Muss HB, Woolf S, Berry D, et al. Adjuvant chemotherapy in older and younger women with lymph node-positive breast cancer. JAMA. 2005;293(9):1073–1081.
   PubMed Web of Science ®Google Scholar
• Biganzoli L, Battisti NML, Wildiers H, et al. Updated recommendations regarding the management of older patients with breast cancer: a joint paper from the European Society of Breast Cancer Specialists (EUSOMA) and the International Society of Geriatric Oncology (SIOG). Lancet Oncol. 2021;22(7):e327–e340.
   PubMed Web of Science ®Google Scholar
• Mohile SG, Dale W, Somerfield MR, et al. Practical Assessment and Management of Vulnerabilities in Older Patients Receiving Chemotherapy: ASCO Guideline for Geriatric Oncology. J Clin Oncol. 2018;36(22):2326–2347.
   PubMed Web of Science ®Google Scholar
• Diab SG, Elledge RM, Clark GM. Tumor characteristics and clinical outcome of elderly women with breast cancer. J Natl Cancer Inst. 2000;92(7):550–556.
   PubMed Web of Science ®Google Scholar
• Wildiers H, Kunkler I, Biganzoli L, et al. Management of breast cancer in elderly individuals: recommendations of the International Society of Geriatric Oncology. Lancet Oncol. 2007;8(12):1101–1115.
   PubMed Web of Science ®Google Scholar
• Biganzoli L, Wildiers H, Oakman C, et al. Management of elderly patients with breast cancer: updated recommendations of the International Society of Geriatric Oncology (SIOG) and European Society of Breast Cancer Specialists (EUSOMA). Lancet Oncol. 2012;13(4):e148–160.
   PubMed Web of Science ®Google Scholar
• Aapro M, Wildiers H. Triple-negative breast cancer in the older population. Ann Oncol. 2012;23(Suppl 6):vi52–55.
   PubMedGoogle Scholar
• Engels CC, Kiderlen M, Bastiaannet E, et al. The clinical prognostic value of molecular intrinsic tumor subtypes in older breast cancer patients: a FOCUS study analysis. Mol Oncol. 2016;10(4):594–600.
   PubMedGoogle Scholar
• Ueno T, Emi M, Sato H, et al. Genome-wide copy number analysis in primary breast cancer. Expert Opin Ther Targets. 2012;16 Suppl 1:S31–35.
   PubMedGoogle Scholar
• Azim HA, Nguyen B, Brohee S, Zoppoli G, Sotiriou C. Genomic aberrations in young and elderly breast cancer patients. BMC Med. 2015;13:266.
   PubMed Web of Science ®Google Scholar
• Guo C, Chen LH, Huang Y, et al. KMT2D maintains neoplastic cell proliferation and global histone H3 lysine 4 monomethylation. Oncotarget. 2013;4(11):2144–2153.
   PubMedGoogle Scholar
• Carroll JS, Liu XS, Brodsky AS, et al. Chromosome-wide mapping of estrogen receptor binding reveals long-range regulation requiring the forkhead protein FoxA1. Cell. 2005;122(1):33–43.
   PubMed Web of Science ®Google Scholar
• Azim HA, Partridge AH. Biology of breast cancer in young women. Breast Cancer Res. 2014;16(4):427.
   PubMed Web of Science ®Google Scholar
• Feng F, Wei Y, Zheng K, et al. Comparison of epidemiological features, clinicopathological features, and treatments between premenopausal and postmenopausal female breast cancer patients in western China: a retrospective multicenter study of 15,389 female patients. Cancer Med. 2018;7(6):2753–2763.
   PubMedGoogle Scholar
• Nasrazadani A, Marti JLG, Kip KE, et al. Breast cancer mortality as a function of age. Aging. 2022;14(3):1186–1199.
   PubMedGoogle Scholar
• Lavelle K, Downing A, Thomas J, Lawrence G, Forman D, Oliver SE. Are lower rates of surgery amongst older women with breast cancer in the UK explained by co-morbidity? Br J Cancer. 2012;107(7):1175–1180.
   PubMed Web of Science ®Google Scholar
• Ward SE, Richards PD, Morgan JL, et al. Omission of surgery in older women with early breast cancer has an adverse impact on breast cancer-specific survival. Br J Surg. 2018;105(11):1454–1463.
   PubMedGoogle Scholar
• Morgan JL, Walters SJ, Collins K, et al. What influences healthcare professionals’ treatment preferences for older women with operable breast cancer? An application of the discrete choice experiment. Eur J Surg Oncol. 2017;43(7):1282–1287.
   PubMedGoogle Scholar
• Wyld L, Reed MWR, Collins K, et al. Bridging the age gap in breast cancer: cluster randomized trial of two decision support interventions for older women with operable breast cancer on quality of life, survival, decision quality, and treatment choices. Br J Surg. 2021;108(5):499–510.
   PubMedGoogle Scholar
• Yang R, Wu Y, Qi Y, et al. A nomogram for predicting breast cancer specific survival in elderly patients with breast cancer: a SEER population-based analysis. BMC Geriatr. 2023;23(1):594.
   PubMedGoogle Scholar
• Hurria A, Magnuson A, Gross CP, et al. Development and validation of a chemotherapy toxicity (Chemo Tox) risk score for older patients (Pts) with breast cancer (BC) receiving adjuvant/neoadjuvant treatment (Adjuvant Tx): a R01 and BCRF funded prospective multicenter study. Cancer Res. 2019;79(4).
   Google Scholar
• Lee SJ, Lindquist K, Segal MR, Covinsky KE. Development and validation of a prognostic index for 4-year mortality in older adults. JAMA. 2006;295(7):801–808.
   PubMed Web of Science ®Google Scholar
• Carey EC, Covinsky KE, Lui LY, Eng C, Sands LP, Walter LC. Prediction of mortality in community-living frail elderly people with long-term care needs. J Am Geriatr Soc. 2008;56(1):68–75.
   PubMed Web of Science ®Google Scholar
• Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A combined comorbidity score predicted mortality in elderly patients better than existing scores. J Clin Epidemiol. 2011;64(7):749–759.
   PubMed Web of Science ®Google Scholar
• Schonberg MA, Davis RB, McCarthy EP, Marcantonio ER. External validation of an index to predict up to 9-year mortality of community-dwelling adults aged 65 and older. J Am Geriatr Soc. 2011;59(8):1444–1451.
   PubMedGoogle Scholar
• Magnuson A, Sedrak MS, Gross CP, et al. Development and Validation of a Risk Tool for Predicting Severe Toxicity in Older Adults Receiving Chemotherapy for Early-Stage Breast Cancer. J Clin Oncol. 2021;39(6):608–618.
   PubMedGoogle Scholar
• Hurria A, Soto-Perez-de-Celis E, Blanchard S, et al. A Phase II Trial of Older Adults With Metastatic Breast Cancer Receiving nab-Paclitaxel: melding the Fields of Geriatrics and Oncology. Clin Breast Cancer. 2019;19(2):89–96.
   PubMedGoogle Scholar
• Yuan Y, Lee JS, Yost SE, et al. Phase II study of neratinib in older adults with HER2 amplified or HER2/3 mutated metastatic breast cancer. J Geriatr Oncol. 2021;12(5):752–758.
   PubMedGoogle Scholar
• Extermann M, Boler I, Reich RR, et al. Predicting the risk of chemotherapy toxicity in older patients: the Chemotherapy Risk Assessment Scale for High-Age Patients (CRASH) score. Cancer. 2012;118(13):3377–3386.
   PubMed Web of Science ®Google Scholar
• Xu B, Zhang Q, Zhang P, et al. Dalpiciclib or placebo plus fulvestrant in hormone receptor-positive and HER2-negative advanced breast cancer: a randomized, Phase 3 trial. Nat Med. 2021;27(11):1904–1909.
   PubMedGoogle Scholar
• Bardia A, Hurvitz SA, DeMichele A, et al. Phase I/II Trial of Exemestane, Ribociclib, and Everolimus in Women with HR(+)/HER2(-) Advanced Breast Cancer after Progression on CDK4/6 Inhibitors (TRINITI-1). Clin Cancer Res. 2021;27(15):4177–4185.
   PubMedGoogle Scholar
• Xu ZQ, Zhang Y, Li N, et al. Efficacy and safety of lapatinib and trastuzumab for HER2-positive breast cancer: a systematic review and meta-analysis of randomised controlled trials. BMJ Open. 2017;7(3).
   Google Scholar
• Li L, Zhang D, Wu Y, Wang J, Ma F. Efficacy and safety of trastuzumab with or without a tyrosine kinase inhibitor for HER2-positive breast cancer: a systematic review and meta-analysis. Biochim Biophys Acta Rev Cancer. 2023;1878(6):188969.
   PubMedGoogle Scholar
• Tutt ANJ, Garber JE, Kaufman B, et al. Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer. N Engl J Med. 2021;384(25):2394–2405.
   PubMed Web of Science ®Google Scholar
• Cejuela M, Vethencourt A, Pernas S. Immune Checkpoint Inhibitors and Novel Immunotherapy Approaches for Breast Cancer. Curr Oncol Rep. 2022;24(12):1801–1819.
   PubMedGoogle Scholar
• Johnston SRD, Harbeck N, Hegg R, et al. Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE). J Clin Oncol. 2020;38(34):3987–3998.
   PubMed Web of Science ®Google Scholar